Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6449223 | 0.87 | LMNA (0.31) | LMNATSHR | |
| SCHEMBL499731 | 0.77 | USP2 (0.48) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| Trifluoroacetic Acid SCHEMBL6450198 | 0.76 | HRH4 (0.30) | — | |
| Trifluoroacetic Acid SCHEMBL6019871 | 0.76 | — | — | |
| SCHEMBL6018741 | 0.75 | LIMK2 (0.31) | — | |
| SCHEMBL6018742 | 0.75 | ACACB (0.30) | — | |
| SCHEMBL2105323 | 0.72 | USP2 (0.43) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL500109 | 0.72 | CYP2D6 (0.40) | ALDH1A1LMNATSHR | |
| SCHEMBL576641 | 0.70 | — | — | |
| SCHEMBL9423551 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113683610-B | RET inhibitor, pharmaceutical composition and application thereof | 广东东阳光药业股份有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-113683610-A | RET inhibitor, pharmaceutical composition and application thereof | 广东东阳光药业有限公司 | 2021-11-23 | — | — | CN | disclosed |
| US-20180334453-A1 | ISOINDOLINE DERIVATIVES | VIIV HEALTHCARE UK LIMITED (GB) | 2018-11-22 | — | — | US | disclosed |
| EP-3383863-A1 | ISOINDOLINE DERIVATIVES | ViiV Healthcare UK Limited (GB) | 2018-10-10 | — | — | EP | disclosed |
| EP-3016934-B1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARM INC (US) | 2018-01-10 | — | — | EP | disclosed |
| US-9695154-B2 | Heteroaryl inhibitors of sumo activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695154-B2 | Heteroaryl inhibitors of sumo activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695154-B2 | Heteroaryl inhibitors of sumo activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| WO-2017093937-A1 | ISOINDOLINE DERIVATIVES | VIIV HEALTHCARE UK LIMITED (GB) | 2017-06-08 | — | — | WO | disclosed |
| US-20160355504-A1 | HETEROARYL INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-12-08 | — | — | US | disclosed |
| WO-2015002994-A2 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-01-08 | — | — | WO | disclosed |
| US-20130078256-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2013-03-28 | — | — | US | disclosed |
| US-20130078256-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2013-03-28 | — | — | US | disclosed |
| US-8334295-B2 | Pyrimidine derivatives as HIV reverse transcriptase inhibitors | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-12-18 | — | — | US | disclosed |
| US-8334295-B2 | Pyrimidine derivatives as HIV reverse transcriptase inhibitors | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-12-18 | — | — | US | disclosed |
| US-20110076276-A1 | Novel HIV reverse transcriptase inhibitors | GILEAD SCIENCES, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-20110076276-A1 | Novel HIV reverse transcriptase inhibitors | GILEAD SCIENCES, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| CN-101784532-A | Novel HIV reverse transcriptase inhibitors | GILEAD SCIENCES INC | 2010-07-21 | — | — | CN | disclosed |
| EP-2167476-A2 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | Korea Research Institute Of Chemical Technology (KR) | 2010-03-31 | — | — | EP | disclosed |
| WO-2009005674-A2 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110076276-A1 | Novel HIV reverse transcriptase inhibitors | POLR2E, POLR1E, POLR2H | KDM4E 790/4885USP2 4582/4885ALDH1A1 1800/4885 |
| US-20130078256-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | POLR2E, POLR1E, POLR2H | KDM4E 790/4885USP2 4582/4885ALDH1A1 1800/4885 |
| US-20180334453-A1 | ISOINDOLINE DERIVATIVES | IRF3, EIF2AK2, MAVS | KDM4E 4157/4885USP2 4221/4885ALDH1A1 491/4885 |
| US-20160355504-A1 | HETEROARYL INHIBITORS OF SUMO ACTIVATING ENZYME | SAE1, SUMO2, SUMO1 | KDM4E 1335/4885USP2 60/4885ALDH1A1 1991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.